Background-High dose inhaled glucocorticosteroids are increasingly used in the management of patients with moderate to severe asthma. Although effective, they may cause systemic side effects. Fluticasone propionate is a topically active inhaled glucocorticosteroid which has few systemic effects at high doses. Methods-Fluticasone propionate, 1.5 mg per day, was compared with beclomethasone dipropionate at the same dose for one year in patients with symptomatic moderate to severe asthma; 142 patients received fluticasone propionate and 132 received beclomethasone dipropionate. The study was multicentre, double blind and of a parallel design. For the first three months patients attended the clinic every four weeks and completed daily diary cards. For the next nine months they were only seen at three monthly intervals in the clinic. Results-During the first three months diary card peak expiratory flow (PEF) rate and lung function measurements in the clinic showed significantly greater improvement in patients receiving fluticasone propionate (difference in morning PEF 15 Vmin (95% CI 6 to 25)), and these differences were apparent at the end of the first week. The improved lung function was maintained throughout the 12 month period and the number of severe exacerbations in patients receiving fluticasone propionate was reduced by 8% compared with those receiving beclomethasone dipropionate. No significant differences between the two groups were observed in morning plasma cortisol levels, urinary free cortisol levels, or response to synthetic ACTH stimulation. In addition, both the rates of withdrawal and of adverse events were low, and there were fewer exacerbations of asthma with fluticasone propionate than beclomethasone dipropionate.
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Conclusions-This study shows that fluticasone propionate in a daily dose of 15 mg results in a significantly greater increase in PEF and asthma control than the same dose of beclomethasone dipropionate, with no increase in systemic or other side effects.
(Thorax 1993;48:817-823)
Inhaled glucocorticosteroids are now considered to be first line regular therapy for asthma.' It is recommended that any patient requiring daily relief with a /12 adrenoceptor agonist (fi2 agonist) should be considered for inhaled prophylactic therapy (glucocorticosteroids or sodium cromoglycate). This would mean that between 50% and 75% of treated asthmatic patients may require inhaled glucocorticosteroids (patient based data, AAH Meditel/Compufile, 1991). In many patients reasonable management of the disease can be achieved with doses of inhaled glucocorticosteroid up to 400 ,ug twice daily. It is generally agreed, however, that treatment should be titrated according to the severity of symptoms and that, in patients with persistent asthma, the dose of inhaled steroid should be increased to achieve optimum control of the patient's condition.' Once the patient's symptoms and peak flow rate have improved, the dose is reduced to the minimum required to maintain control. Higher doses of inhaled steroid are also used in patients who require a reduction in the dose of their oral steroid therapy.23
Inhaled steroids are usually well tolerated but, as the dose increases, so too does the likelihood of systemic side effects, particularly hypothalamic pituitary adrenal (HPA) axis suppression, osteoporosis, and growth retardation. 4 It is recognised that inhaled steroid therapy could be improved with the introduction of drugs with higher topical potency and reduced local and systemic side effects.
Fluticasone propionate is a trifluorinated glucocorticoid which has been developed for use as an inhaled preparation for the treatment of asthma. Fluticasone propionate has chemical modifications which decrease mineralocorticoid activity and increase potency and lipophilicity. It has more than nine times the activity of fluocinolone acetonide and twice the activity of beclomethasone dipropionate in the McKenzie skin vasoconstrictor assay in humans.5 Furthermore, fluticasone propionate is poorly absorbed following oral administration. The small portion of drug which is absorbed is metabolised rapidly by the liver into inactive metabolites. The hepatic extraction ratio of fluticasone propionate is almost 100%, giving the drug an oral bioavailability of <1%. This compares favourably with the bioavailability of budesonide (11%), flunisolide (20%), and dexamethasone and prednisolone (>80%).6 Since up to 90% of an inhaled dose may be swallowed if a spacing chamber is not used, fluticasone propionate appears to have an advantage over existing inhaled corticosteroids. There is no evidence for local metabolism in the lung.
This study was designed to compare the efficacy and safety of fluticasone propionate with an equal daily dose of beclomethasone dipropionate. Preclinical and clinical studies have suggested that fluticasone propionate has at least twice the potency of beclomethasone dipropionate with a greater local to systemic activity ratio. pregnancy or lactation. Women of childbearing potential were only included if the investigator considered that they were taking adequate contraceptive precautions. All patients gave their informed consent and the study was approved by local ethical committees.
STUDY DESIGN
During the two week run in period the patients discontinued use of their usual inhaled corticosteroid therapy and received 1-5 mg beclomethasone dipropionate per day. The dose of all other asthma medication remained constant, except for inhaled /52 agonists which were only to be continued on an "as required" basis. If, during that period, the patients achieved the criteria for randomisation they entered the double blind portion of the study. These patients were randomly allocated in a double blind manner to receive either fluticasone propionate, 1-5 mg/day, or beclomethasone dipropionate, 1-5 mg per day, for one year. Investigators were, however, permitted to increase the dose of study drug to 2 mg at any time after the first three months, either transiently or long term. For the first three months the patients attended the clinic every four weeks and completed daily diary cards. After this they were seen at three monthly intervals in the clinic and did not complete daily assessments. They were also seen at a follow up visit two weeks after withdrawal of study medication.
Measurements
Using the mini Wright peak flow meter, patients measured their PEF in the morning (between 07 00 and 08-00 hours) before using a bronchodilator, and in the evening (19-00-20-00 hours), preferably not within four hours of bronchodilator therapy. On each occasion they took three readings and entered the highest measurement on a daily record card on which they also noted the severity of their asthma symptoms by day and at night, using four-point rating scales. Symptoms during the day were rated as 0 = very well, no symptoms; 1 = a few symptoms (not troublesome); 2 = asthma troublesome; or 3 = asthma bad, not able to carry out daily activities as normal. Symptoms during the night were rated as: 0 = slept through the night; 1 = slept well, woken early or once by asthma or cough; 2 = woken two or three times by cough or asthma; or 3 = bad night, kept awake most of the night by asthma.
Patients also recorded their use of the study medication and of the salbutamol inhaler.
At each of the clinic visits three measure- Adverse events At each clinic visit assessments of safety were performed. All serious and minor adverse events were recorded, irrespective of their apparent cause in relation to the study drug.
Laboratory evaluations
At the prestudy visit, at the end of the run in period, and after three, six, nine, and 12 months, patients were asked to collect a 24 hour urine sample for determination of urinary free cortisol excretion. Blood samples for routine testing (haematology, biochemistry) were taken between 08-00 and 10 00 hours at the clinic visits before and during treatment, and at the follow up visit if any abnormal results had been noted at the previous visit. The samples were analysed locally. Plasma cortisol concentrations were assessed from blood samples taken at the pretrial visit and at all other visits throughout the 12 months of study. The plasma cortisol samples were analysed by radioimmunoassay at the West Middlesex Laboratory, UK using the coated tube method with a between batch coefficient of variation of 7%.
In addition, at some centres patients had assessments of adrenal reserve made using a short tetracosactrin test after 12 months of treatment. Patients were asked to withhold treatment with inhaled glucocorticosteroids for at least 12 hours before the test. A blood sample was taken between 08-00 and 10-00 hours for determination of basal plasma cortisol concentration. Patients then received a single intramuscular injection of tetracosactrin 250 pg. Exactly 30 and 60 minutes later further blood samples were obtained for plasma cortisol measurements.
Asthma exacerbations Asthma exacerbations were defined as increasing asthma symptoms requiring a change in therapy other than inhaled fl2 agonist rescue therapy, and these were recorded throughout the study by the investigators. The occurrence of an exacerbation was not a dropout criterion so the patient could continue in the study at the doctor's discretion. The procedure to be followed in the event of an exacerbation of asthma was detailed in the protocol and explained to the patients. 3) , and the adjusted treatment difference was greater on fluticasone propionate by 0-15 1 (95% CI 0-01 to 0-29; p < 0-05). Significant treatment differences in favour of fluticasone propionate were also found after eight and 12 weeks of treatment (p < 0-05).
Mean FVC values showed a similar increase from 3-37 1 and 2-89 1 for fluticasone propionate and beclomethasone dipropionate groups to 3-56 1 and 3-04 1, respectively. The adjusted mean differences, both between absolute values and as a percentage of predicted normal values, were not significantly different at any of the clinic visits.
Asthma exacerbations
The number of patients experiencing an exacerbation of asthma during the study is shown in table 2. The number of exacerbations Cortisols Analysis of geometric mean plasma cortisol values at baseline and after three, six, nine, and 12 months include only those patients with data at baseline and at the specified visit. There was no difference between the geometric mean plasma cortisol concentrations in patients receiving fluticasone propionate and beclomethasone dipropionate at any of the visits (table 3) , nor were there any differences in the percentage of patients with a plasma cortisol level below the lower limit of normal (150 nmol/1). Likewise there were no differences between treatment groups in the 24 hour urinary free cortisol levels; 25/110 (23%) patients treated with fluticasone propionate and 26/115 (23%) treated with beclomethasone dipropionate showed a change from high or normal values to below the lower limit of the normal range. The tetracosactrin test was performed in 35 and 30 patients in the fluticasone propionate and beclomethasone dipropionate groups respectively, after 12 months of treatment. The results from both treatment groups showed a "normal response"-that is, after 30 minutes mean plasma cortisol concentrations had risen by at least 200 nmol/l to almost 500 nmol/l and after 60 minutes were greater than 500 nmol/l.
Adverse events There were no consistent changes in biochemical or haematological indices on either treatment. During the study there were 276 and 267 adverse events during treatment with fluticasone propionate and beclomethasone dipropionate in 70% and 73% of patients, respectively. This included serious adverse events in 16% and 23% for fluticasone propionate and beclomethasone dipropionate respectively, leading to 8% of patients withdrawing in both groups. There were three deaths during the study, two while receiving fluticasone propionate and one while receiving beclomethasone dipropionate, none of which were asthma related. The adverse events which occurred most commonly-that is, more than 5%-and those which were pharmacologically predictable are shown in table 4. The most common were related to the patient's disease (asthma, rhinitis). The incidence of expected pharmacologically predictable adverse events such as Candida infec- Several national' and international'7 guiderere not significant and lines recommend the use of inhaled glucocorn the two treatment ticosteroid as first line prophylactic therapy. If these gain acceptance they will lead to greater numbers of asthmatic patients taking such drugs. Already in the UK more than 50% of treated asthmatic patients receive inhaled that a daily dose of glucocorticosteroids. The guidelines recom-)ropionate causes a mend treatment in a stepwise manner. To i diary card and clinic achieve the goals of asthma management, rements than 1-5 mg plans such as abolition of symptoms will -opionate in adult therefore require that some patients receive te to severe asthma. higher doses of glucocorticosteroids than are )rovement with fluti-currently given as maintenance. Indeed, this more rapidly apparent study has shown that patients taking at least hasone dipropionate, 1 mg/day beclomethasone dipropionate or first week. There was budesonide who, in addition, were regularly nptom scores and res-taking / agonist and/or oral methylxanthines be reduced more on showed considerable improvement in lung than on beclometha-function and symptom scores when their dose .iough only the differ-of inhaled glucocorticosteroid was increased. was significant. These The change to higher doses in greater num-I in patients who were bers of patients will therefore require the use )00 and 2000,ug/day of drugs with the greatest margin of safety.
)ionate or budesonide The potential hazards from extended use of :udy and then had a inhaled glucocorticosteroids were highlighted eriod on 1 5 mg/day by Brown et al '4 and Boe and Skoogh'6 who )ionate. The improve-concluded that more long term studies are U was maintained over required.
The results of this study suggest that fluticasone propionate may be more effective than beclomethasone dipropionate. This, taken together with the observation that it has minimal effect on the HPA axis function at high doses, suggests that fluticasone propionate will be of benefit in the long term treatment of asthma. 
